Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydralazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | GOT1 | P17174 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | MPO | P05164 | 2/20 | 0.76 |
| ▸ | MAOA | P21397 | 2/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | THPO | P40225 | 1/20 | 0.76 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.76 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydralazine SCHEMBL3995896 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL7810 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL4711942 | 0.86 | NPC1 (0.56) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL2780318 | 0.85 | ALDH1A1 (0.89) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL1173534 | 0.85 | GOT1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL27864907 | 0.85 | GOT1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL36271 | 0.85 | GOT1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL2779460 | 0.84 | NPC1 (0.81) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL8703662 | 0.84 | ALDH1A1 (0.81) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Dihydralazine SCHEMBL13724517 | 0.84 | ALDH1A1 (0.93) | ALDH1A1LMNANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NICOX S.A. | 2004-07-29 | — | — | US | disclosed |
| US-6645965-B1 | Sildenafil, hydralazine, minoxidil, or zaprinast; cardiovascular disorders | NICOX S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NOS2, NOS1, NOS3 | ALDH1A1 698/4885LMNA 2531/4885NPC1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.